Canada markets open in 4 hours 10 minutes

Hamilton Thorne Ltd. (HTL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
1.7400-0.0100 (-0.57%)
At close: 3:10PM EDT
Full screen
Previous Close1.7500
Open1.7500
Bid1.7000 x 0
Ask1.7400 x 0
Day's Range1.7100 - 1.7500
52 Week Range1.0200 - 1.8400
Volume10,872
Avg. Volume110,906
Market Cap241.684M
Beta (5Y Monthly)1.00
PE Ratio (TTM)193.33
EPS (TTM)0.0090
Earnings DateApr. 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
  • Hamilton Thorne Announces Dr. Thomas Ebner and Cynthia Hudson to Join Its Scientific Advisory Board
    GlobeNewswire

    Hamilton Thorne Announces Dr. Thomas Ebner and Cynthia Hudson to Join Its Scientific Advisory Board

    BEVERLY, Mass. and TORONTO, April 15, 2021 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced the strengthening of its Scientific Advisory Board with the appointments of Dr. Thomas Ebner and Cynthia Hudson. David Wolf, President and CEO of Hamilton Thorne Ltd., commented, “We are pleased to welcome Thomas and Cynthia to our Scientific Advisory Board. They are both accomplished clinicians with invaluable knowledge who will serve as a strategic resource for Hamilton Thorne and provide scientific review and high-level advice about the company’s scientific, product, and commercial initiatives.” Thomas Ebner, PhD, is an ESHRE-certified Senior Clinical Embryologist (2008) with 25 years of hands-on experience in IVF laboratories. He served as board member of Alpha – Scientists in Reproductive Medicine for 3 years and is currently a member of the Executive Board of ESHRE (2017-2021). Dr. Ebner edited or co-edited two books and has published more than 15 book chapters and 150 papers in national and international peer-reviewed journals. His main scientific interests include culture media, assisted oocyte activation, time-lapse technology, and oocyte competence. Cynthia Hudson is the Executive Director of Embryology, Strategy, and Operations for TMRW Life Sciences, a company that created the world’s first and only automated platform for the management and storage of cryopreserved fertility tissue. Her experiences in the design and buildout of new fertility practices led her to establish one of the first embryologist-owned-and-operated IVF centers in New York City. She’s launched two licensed medical practices, owns a laboratory consulting company, and is a co-founder of KindBody, the ground-breaking startup that has disrupted the fertility space with novel pricing and woman-centered care. Cynthia holds a Master of Science degree in Clinical Embryology from the University of Leeds in England. She is a member of the American Association of Bioanalysts (AAB), American Society for Reproductive Medicine (ASRM), European Society of Human Reproduction and Embryology (ESHRE), and the American College of Embryology (EMBCOL). About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd) Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments. Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release. For more information, please contact: David Wolf, President & CEOHamilton Thorne Ltd. 978-921-2050 ir@hamiltonthorne.ltd Michael Bruns, CFO Hamilton Thorne Ltd. 978-921-2050 ir@hamiltonthorne.ltd Glen AkselrodBristol Investor Relations905-326-1888glen@bristolir.com

  • Hamilton Thorne to Participate in Bloom Burton & Co. Healthcare Investor Conference on April 20-21, 2021
    GlobeNewswire

    Hamilton Thorne to Participate in Bloom Burton & Co. Healthcare Investor Conference on April 20-21, 2021

    BEVERLY, Mass. and TORONTO, April 13, 2021 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that the company will participate in the Bloom Burton & Co. Healthcare Investor Conference on April 20-21, 2021. David Wolf, President and CEO of Hamilton Thorne Ltd., will represent the company at a virtual presentation to be held at 2:30 PM EDT on Wednesday April 21, 2021 and will be available for virtual one-on-one meetings during both days of the conference. To schedule a meeting with management, please contact your conference representative or email ir@hamiltonthorne.ltd. Equity Grants The Company also announced that on April 12, 2021 it granted a total of 705,500 stock options to purchase common shares and 855,149 restricted share units (RSUs) pursuant to the Company’s 2019 Long-Term Equity Incentive Plan (the “Plan”). The options are exercisable at Cdn $1.75 per share and expire ten years from the date of grant. Each vested RSU entitles the holder to receive one common share of the Company in accordance with the Plan. A total of 711,477 RSUs were granted to the Company’s Directors, CEO, CTO, and CFO. Option grants vest over four years and RSUs over three years. About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd) Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments. Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release. For more information, please contact: David Wolf, President & CEOMichael Bruns, CFOGlen AkselrodHamilton Thorne Ltd.Hamilton Thorne Ltd.Bristol Investor Relations978-921-2050978-921-2050905-326-1888ir@hamiltonthorne.ltdir@hamiltonthorne.ltdglen@bristolir.com

  • ACCESSWIRE

    Hamilton Thorne Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 8, 2021 / Hamilton Thorne Ltd. (OTC PINK:HTLZF) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on April 8, 2021 at 11:00 AM Eastern Time.